Bausch Health Companies reported $20.72B in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Amgen USD 57.3B 19M Jun/2026
ANI Pharmaceuticals USD 607.23M 3.26M Sep/2026
Aurora Cannabis CAD 22.68M 1.18M Jun/2026
Bausch Health Companies USD 20.72B 64M Sep/2026
Biogen USD 7.69B 398.3M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Canopy Growth CAD 277.33M 1.38M Jun/2026
Corcept Therapeutics USD 8.99M 430K Sep/2026
Danaher USD 26.48B 76M Sep/2026
Drreddys Laboratories INR 72.29B 5.05B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 293.59M 69.53M Sep/2026
Perrigo USD 3.29B 337.7M Jun/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 2.07B 1.02B Jun/2026
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026
Zoetis USD 9.24B 0 Jun/2026